Enacted — Signed by the President — Aug 7, 2015
Last Action: Signed by President.
Explanation: This bill was enacted after being signed by the President on August 7, 2015.
Jun 26, 2007
110th Congress, 2007–2009
This bill was introduced on June 27, 2007, in a previous session of Congress, but was not enacted.
Senator from Massachusetts
Read Text »
Last Updated: Nov 19, 2008
Length: 88 pages
A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes.
The “S.” in “S. 1695” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The bill’s title was written by its sponsor.
The committee chair determines whether a bill will move past the committee stage.
There have been no votes related to this bill.
Search for similar bills.
Click a format for a citation suggestion:
Civic Impulse. (2015). S. 1695 — 110th Congress: Biologics Price Competition and Innovation Act of 2007. Retrieved from https://www.govtrack.us/congress/bills/110/s1695
“S. 1695 — 110th Congress: Biologics Price Competition and Innovation Act of 2007.” www.GovTrack.us. 2007. September 4, 2015 <https://www.govtrack.us/congress/bills/110/s1695>
|title=S. 1695 (110th)
|accessdate=September 4, 2015
|author=110th Congress (2007)
|date=June 26, 2007
|quote=Biologics Price Competition and Innovation Act of 2007